Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 12/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 9/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10343416 | 1.00 | MEN1 (0.52) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8748862 | 0.98 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL242586 | 0.98 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8748934 | 0.98 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8761610 | 0.98 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL3425106 | 0.98 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8754825 | 0.98 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8749215 | 0.98 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8761736 | 0.98 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8748944 | 0.98 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0187052-B1 | ADAMANTAN AMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | S.A. PANMEDICA Société dite: (FR) | 1990-01-31 | — | — | EP | claimed |
| JP-6145141-A | — | — | None | — | — | JP | disclosed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230414481-A1 | Composition and Method for Producing Same and Cosmetic Agent | ASAHI KASEI FINECHEM CO., LTD. (JP) | 2023-12-28 | — | — | US | disclosed |
| EP-4239037-A1 | COMPOSITION, METHOD FOR PRODUCING SAME, AND COSMETIC | Asahi Kasei Finechem Co., Ltd. (JP) | 2023-09-06 | — | — | EP | disclosed |
| CN-116507696-A | Composition, method for producing same, and cosmetic | 旭化成精细化工股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-11377443-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2022-07-05 | — | — | US | disclosed |
| US-20200407349-A1 | PHARMACEUTICAL COMPOUNDS | CellCentric Limited (GB) | 2020-12-31 | — | — | US | disclosed |
| US-10696666-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2020-06-30 | — | — | US | disclosed |
| US-10647704-B2 | Pharmaceutical compounds | CELLCENTRIC LTD (GB) | 2020-05-12 | — | — | US | disclosed |
| CN-110049983-A | Medical compounds | 细胞中心有限公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-110036002-A | Medical compounds | 细胞中心有限公司 | 2019-07-19 | — | — | CN | disclosed |
| US-5472946-A | Topical administration of lincomycin, clindamycin, erthromycin and iododeoxyuridine on skin or mucuous membranes | DISCOVERY THERAPEUTICS, INC. | 1995-12-05 | — | — | US | disclosed |
| US-5470848-A | Penetration enhancers for transdermal delivery of systemic agents | DISCOVERY THERAPEUTICS, INC. | 1995-11-28 | — | — | US | disclosed |
| US-5444075-A | Penetration enhancers for transdermal delivery of systemic agents | MINASKANIAN GEVORK (US) | 1995-08-22 | — | — | US | disclosed |
| JP-H06145141-A | N-ACYL-2-PYRROLIDONE-5-CARBOXYLIC ACID ESTER | AJINOMOTO CO INC | 1994-05-24 | — | — | JP | disclosed |
| US-5234959-A | Omega-dialkylaminoalkanoic acids; drug delivery directly to the bloodstream | WHITBY RESEARCH, INC. (US) | 1993-08-10 | — | — | US | disclosed |
| US-5118676-A | Administering carboxylic derivatives as enhancer with systemically active agents | WHITBY RESEARCH, INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-5118692-A | Penetration enhances for transdermal delivery of systemic agents | WHITBY RESEARCH, INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-4996199-A | Penetration enhancers for transdermal delivery of systemic agents | WHITBY RESEARCH, INC. (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407349-A1 | PHARMACEUTICAL COMPOUNDS | EP300, HDAC1, HDAC11 | MEN1 1691/4885KMT2A 458/4885POLB 2037/4885 |
| US-20230414481-A1 | Composition and Method for Producing Same and Cosmetic Agent | CUTA, NOTUM, DAGLA | MEN1 802/4885KMT2A 2484/4885POLB 218/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | MEN1 4840/4885KMT2A 2718/4885POLB 2615/4885 |
| US-10647704-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | MEN1 1032/4885KMT2A 214/4885POLB 1379/4885 |
| US-11377443-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | MEN1 1691/4885KMT2A 458/4885POLB 2037/4885 |
| US-10696666-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | MEN1 1691/4885KMT2A 458/4885POLB 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.